Evaluation of a multi-functional nanocarrier for targeted breast cancer iNOS gene therapy.

Helen O. McCarthy, Alek V. Zholobenko, Yuhua Wang, Brenda Canine, Tracy Robson, David G. Hirst, Arash Hatefi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The present study determines whether the novel designer biomimetic vector (DBV) can condense anddeliver the cytotoxic iNOS gene to breast cancer cells to achieve a therapeutic effect. We have previouslyshown the benefits of iNOS for cancer gene therapy but the stumbling block to future development hasbeen the delivery system.The DBV was expressed, purified and complexed with the iNOS gene. The particle size and chargewere determined via dynamic light scattering techniques. The toxicity of the DBV/iNOS nanoparticleswas quantified using the cell toxicity and clonogenic assays. Over expression of iNOS was confirmed viaWestern blotting and Griess test.The DBV delivery system fully condensed the iNOS gene with nanoparticles less than 100 nm. Transfectionwith the DBV/iNOS nanoparticles resulted in a maximum of 62% cell killing and less than 20%clonogenicity. INOS overexpression was confirmed and total nitrite levels were in the range of 18M.We report for the first time that the DBV can successfully deliver iNOS and achieve a therapeuticeffect. There is significant cytotoxicity coupled with evidence of a bystander effect. We concludethat the success of the DBV fusion protein in the delivery of iNOS in vitro is worthy of future in vivo experiments.
Original languageEnglish
Pages (from-to)196-202
Number of pages7
JournalInternational Journal of Pharmaceutics
Volume405
Issue number1-2
DOIs
Publication statusPublished - 28 Feb 2011

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Evaluation of a multi-functional nanocarrier for targeted breast cancer iNOS gene therapy.'. Together they form a unique fingerprint.

  • Cite this